Related Experiment Video

Updated: Feb 11, 2026

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

1.2K

Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas

Francisco Bautista1, Angelo Paci, Veronique Minard-Colin

  • 1Pediatric and Adolescent Oncology Department, Gustave Roussy, Villejuif, France.

Pediatric Blood & Cancer
|December 31, 2013
PubMed

Insights

Vemurafenib shows promise in treating pediatric high-grade gliomas with BRAFV600E mutations. One patient achieved partial tumor response and clinical improvement, remaining alive 20 months after treatment.

Area of Science:

  • Pediatric oncology
  • Molecular oncology
  • Neuro-oncology

Background:

  • High-grade gliomas (HGGs) in children are rare and aggressive brain tumors.
  • BRAFV600E mutations are identified as potential oncogenic drivers in certain pediatric gliomas.
  • Targeted therapies are being explored to improve outcomes for these young patients.

Observation:

  • Three pediatric patients with BRAFV600E-mutant high-grade gliomas received vemurafenib treatment.
  • One patient with anaplastic ganglioglioma showed a partial tumor response and clinical improvement, with survival extending to 20 months.
  • Another patient with ganglioglioma had a transient response upon vemurafenib re-introduction post-immunotherapy.

Findings:

  • Pharmacokinetic data indicate that vemurafenib's maximum concentration and steady-state exposure are dose-dependent and comparable between pediatric and adult patients.
  • BRAFV600E mutations appear to be a significant oncogenic driver in pediatric gliomas, suggesting a target for therapy.
  • Vemurafenib demonstrated clinical benefit in at least one pediatric patient with BRAFV600E-mutant glioma.

Implications:

  • These findings support the role of BRAFV600E as an oncogenic driver in pediatric gliomas.
  • Vemurafenib represents a potential targeted therapy option for pediatric gliomas harboring BRAFV600E mutations.
  • Further clinical investigation is warranted to establish the efficacy and safety of vemurafenib in this patient population.
Keywords:
BRAF mutationsanaplastic gangliogliomapediatric brain tumorspharmacokineticsvemurafenib

More Related Videos

Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions07:39

Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions

Published on: November 17, 2021

4.0K
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.5K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
330
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
307
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
245
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
274
Mutations01:39

Mutations

Overview
94.6K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.6K